Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
These observations are procedural in nature and none of them are related to data integrity
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
The Q1 2025 also witnessed a successful launch of Allegra D
Alembic Pharmaceuticals commissions new facility at Pithampur
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The Subsidiary has received one inspectional observation in Form 483
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
Subscribe To Our Newsletter & Stay Updated